Hengrui and Kailera's oral GLP-1 pill shows promising efficacy but notable side effects in Chinese obesity and diabetes trials

Hengrui Pharma and Kailera Therapeutics reported results from two late‑stage trials in China, one targeting obesity and the other diabetes, using their daily oral GLP‑1 pill. The studies demonstrated that the pill can produce meaningful weight loss in obese participants and improve blood‑sugar control in diabetic patients, meeting the primary efficacy endpoints.

In the obesity trial, participants achieved an average weight reduction that compares favorably with existing injectable GLP‑1 therapies. The diabetes study showed a statistically significant drop in HbA1c levels, indicating better glycemic management.

However, both trials recorded a high rate of adverse events, primarily gastrointestinal in nature, leading to discontinuations for a notable proportion of subjects. The safety profile raises questions about the pill’s tolerability compared with injectable counterparts.

The mixed outcomes suggest that while the oral formulation could expand the GLP‑1 market if safety issues are mitigated, further work will be needed to address side‑effect concerns before broader regulatory approval or commercial launch.